SCHEMBL12437418

SCHEMBL12437418

CC1CCCCN1CCNC(=O)c1cccc(OC2CCCN(CC(c3ccccc3)c3ccccc3)C2)c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
SLC5A7 Q9GZV3 1/20 0.49
ALDH1A1 P00352 5/20 0.47
KDM4E B2RXH2 5/20 0.47
GLA P06280 2/20 0.47
GAA P10253 2/20 0.47
MAPK1 P28482 2/20 0.47
MAPT P10636 2/20 0.47
CCR3 P51677 1/20 0.46
HSD17B10 Q99714 3/20 0.44
USP2 O75604 1/20 0.44
TSHR P16473 1/20 0.44
LMNA P02545 1/20 0.43
CHRM1 P11229 2/20 0.43
DRD4 P21917 1/20 0.43
HRH3 Q9Y5N1 1/20 0.42
CCR2 P41597 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12437459 0.95 MEN1 (0.49) KMT2AMEN1SLC5A7ALDH1A1KDM4E
SCHEMBL12437439 0.92 KMT2A (0.60) KMT2AMEN1SLC5A7ALDH1A1KDM4E
SCHEMBL12437374 0.90 SLC5A7 (0.53) KMT2AMEN1SLC5A7CCR3DRD4
SCHEMBL12437436 0.90 SLC5A7 (0.53) KMT2AMEN1SLC5A7CCR3DRD4
SCHEMBL12437423 0.89 MEN1 (0.51) KMT2AMEN1SLC5A7MAPK1CCR3
SCHEMBL12437419 0.89 SLC5A7 (0.54) KMT2AMEN1SLC5A7CCR3DRD4
SCHEMBL12437509 0.87 MEN1 (0.58) KMT2AMEN1SLC5A7ALDH1A1KDM4E
SCHEMBL12437402 0.87 SLC5A7 (0.54) KMT2AMEN1SLC5A7CCR3DRD4
SCHEMBL12437449 0.87 CCR3 (0.53) KMT2AMEN1SLC5A7CCR3TSHR
SCHEMBL12437468 0.87 SLC5A7 (0.51) KMT2AMEN1SLC5A7CCR3TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof AVALON PHARMACEUTICALS 2011-07-21 US disclosed
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof AVALON PHARMACEUTICALS 2011-07-21 US disclosed
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof AVALON PHARMACEUTICALS 2009-02-05 US disclosed
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof AVALON PHARMACEUTICALS 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof HPGDS, HPGD, DPYD KMT2A 2446/4885MEN1 3974/4885SLC5A7 4329/4885
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof HPGDS, HPGD, DPYD KMT2A 2446/4885MEN1 3974/4885SLC5A7 4329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.